September 27, 2024 — After a day of a National Obesity Policy Forum at the Top of the Hill in Washington, it was plain that we have witnessed a profound shift in the conversation about policy to address obesity. No more lip service about nudging America to “eat healthy” as the answer to a high prevalence of this disease. […]
June 21, 2023 — We’re packing our bag for San Diego and the 83rd Scientific Sessions of the American Diabetes Association, which starts on Friday. This is not a meeting that has been a regular habit for ConscienHealth. But this year it seems ADA2023 will be another milestone in the ongoing diabesity merger. That almost too clever term first […]
December 13, 2022 — The American Diabetes Association is out with their new standards of care for 2023 and at the top of the list of seven major changes is a refined focus on obesity. Changes in medical care are subtle and slow. But when you look at how it has evolved over recent years, the shift in views […]
June 6, 2022 — Two ideas are hard to miss at the annual Scientific Sessions of the American Diabetes Association. One is that it’s getting harder to treat and prevent diabetes adequately without treating obesity. Second is that health systems can’t handle this reality. They are systematically preventing adequate obesity and diabetes care. Distinct but Overlapping Diseases Let’s get […]
June 5, 2022 — This is what you might call a clean sweep. At the Scientific Sessions of the ADA and in NEJM yesterday, researchers unveiled detailed data on tirzepatide for obesity. When Lilly gave us a peek at these data a month ago, “Wow!” was our response. With the full details in view and peer reviewed, we tend […]
June 14, 2019 — It was odd. Lilly had a promising new drug for diabetes that delivered unusually good weight outcomes. But they weren’t sure about developing it for obesity. That was last October. Now, though, they seem to have decided to move ahead with their dual GIP/GLP-1 agonist, tirzepatide, for obesity. Pivotal phase 3 trials will begin this […]
June 9, 2019 — Some of the most discussed news coming from the American Diabetes Association Scientific Sessions in San Francisco is all about the PIONEER studies of oral semaglutide. This drug is presently under review at FDA for type 2 diabetes. Interest is keen because it will be the first of its class that doesn’t require an injection. […]
June 18, 2018 — Myth-busting is a popular approach for tackling controversial or misunderstood subjects. Certainly you’ll find a bit of that here at ConscienHealth. We’re not shy about dispelling myths. But Derek Powell and colleagues conclude that myth-busting can become deceptive. If the question at hand is subtle – not starkly true or false – then myth-busting can leave readers […]
March 8, 2018 — Recent news makes it clear. You can be sure that relentless change lies ahead for type 2 diabetes care. The American College of Physicians (ACP, representing 152,000 internists) is fighting with the American Diabetes Association and other experts over the standard of care. And Scandinavian researchers have found that we might do well to split […]
June 25, 2013 — One of the greatest challenges for addressing obesity is delivering evidence-based weight control at a scale that will have meaningful impact. Oh, and we’d like it to be affordable. At the 2013 Scientific Sessions of the American Diabetes Association in Chicago yesterday, a team of researchers presented data suggesting they can do just that in […]
